Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type
PMID
Authors David A. Reardon, Tae-Min Kim, Jean-Sebastien Frenel, Armando Santoro, Juanita Lopez, Deepa S. Subramaniam, Lillian L. Siu, Jordi Rodon, Kenji Tamura, Sanatan Saraf, Anne Morosky, Karen Stein and Jean-Charles Soria
Title RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)
URL http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi25.4.abstract?sid=af283a96-f950-4f1d-a7cb-611b9ddd3325
Abstract Text Neuro Oncol (2016) 18 (suppl 6): vi25-vi26.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive glioblastoma conflicting Pembrolizumab Phase Ib/II Actionable In a Phase Ib trial, Keytruda (pembrolizumab) treatment resulted in partial response in 4% (1/25), stable disease in 48% (12/25), a median progression free survival of 2.8 months, and a median overall survival of 14.4 months in patients with CD274 (PD-L1) positive, bevacizumab-naive recurrent glioblastoma (Neuro Oncol (2016) 18 (suppl 6): vi25-vi26.). detail...